Analyst Price Targets — ZBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2026 9:59 am | Roger Song | Jefferies | $48.00 | $16.61 | StreetInsider | Zenas Biopharma (ZBIO) PT Lowered to $48 at Jefferies, 'we see clear path for approval (BLA submission planned in 2Q and MAA in 2H26') |
| January 5, 2026 8:39 pm | — | Morgan Stanley | $19.00 | $16.61 | TheFly | Zenas BioPharma downgraded to Equal Weight from Overweight at Morgan Stanley |
| October 28, 2025 10:08 am | — | H.C. Wainwright | $44.00 | $29.67 | TheFly | Zenas BioPharma price target raised to $44 from $30 at H.C. Wainwright |
| October 27, 2025 4:32 pm | Sean Laaman | Morgan Stanley | $34.00 | $31.65 | StreetInsider | Zenas Biopharma (ZBIO) PT Raised to $34 at Morgan Stanley |
| October 27, 2025 3:02 pm | Roger Song | Jefferies | $52.00 | $31.80 | StreetInsider | Zenas Biopharma (ZBIO) PT Raised to $52 at Jefferies |
| October 8, 2024 5:18 am | Roger Song | Jefferies | $35.00 | $18.70 | TheFly | Zenas BioPharma initiated with a Buy at Jefferies |
Latest News for ZBIO
WALTHAM, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on February 17, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board…
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation seeks to determine whether Zenas BioPharma's directors breached their fiduciary duties in connection with recent corporate actions.
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) -
Stock News Lilly beats and lifts outlook: Eli Lilly (LLY) posted Q4 revenue of $19.29B (+43%) and adjusted EPS of $7.54, and guided 2026 revenue to $80â$83B a
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZBIO.
U.S. House Trading
No House trades found for ZBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.